Follow the people · Insider
MONTANOVA CAPITAL, LLC
MONTANOVA CAPITAL, LLC files insider transactions with the SEC as a director of Veradermics (MANE). We hold 4 disclosed purchases and sales filed since 5 December 2024, 1 of them in the last 90 days.
- Files forMANE
- Disclosed buys and sells4 in all, 1 in the last 90 days
- Last disclosure21 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 4 February 2026 — 20 August 2026Director · Veradermics (MANE)46 Form 4 lines · source: SEC Form 4
- Filed 3 December 2024 — 7 November 2025Director and 10% owner · Benitec Biopharma (BNTC)8 Form 4 lines · source: SEC Form 4
Everything they disclosed
54 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 690,601 shares of VeradermicsSEC Form 421 August 2026Common stock, par value $0.00001 per share · traded 19 August 2026 · filed 21 August 2026
- ▼ sold on the open market 59,399 shares of VeradermicsSEC Form 421 August 2026Common stock, par value $0.00001 per share · traded 19 August 2026 · filed 21 August 2026
- exercised in-the-money options over 149,000 shares of VeradermicsSEC Form 421 August 2026Common stock, par value $0.00001 per share · traded 20 August 2026 · filed 21 August 2026
- exercised in-the-money options over 151,000 shares of VeradermicsSEC Form 421 August 2026Common stock, par value $0.00001 per share · traded 20 August 2026 · filed 21 August 2026
- exercised in-the-money options over 149,000 shares of Veradermics (a derivative holding)SEC Form 421 August 2026Pre-Funded Warrants · traded 20 August 2026 · filed 21 August 2026
- exercised in-the-money options over 151,000 shares of Veradermics (a derivative holding)SEC Form 421 August 2026Pre-Funded Warrants · traded 20 August 2026 · filed 21 August 2026
- was granted 149,000 shares of Veradermics (a derivative holding)SEC Form 45 May 2026Pre-Funded Warrants · traded 1 May 2026 · filed 5 May 2026
- was granted 151,000 shares of Veradermics (a derivative holding)SEC Form 45 May 2026Pre-Funded Warrants · traded 1 May 2026 · filed 5 May 2026
- ▲ bought on the open market 10,004 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 9,168 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 4,453 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 3,178 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 3,832 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 19,199 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 38,771 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 17,835 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 16,563 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 11,183 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 6 February 2026 · filed 9 February 2026
- ▲ bought on the open market 19,338 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 6 February 2026 · filed 9 February 2026
- ▲ bought on the open market 10,676 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 14,659 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 53,344 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 25,908 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 18,489 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 1,720 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 1,835 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 10,004 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 10,676 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 14,659 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 53,344 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 25,908 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 18,489 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 1,720 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 1,835 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 2,519 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 9,168 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 4,453 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 3,178 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 3,832 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 19,199 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 38,771 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 17,835 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 16,563 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 5 February 2026 · filed 9 February 2026
- ▲ bought on the open market 11,183 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 6 February 2026 · filed 9 February 2026
- ▲ bought on the open market 19,338 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 6 February 2026 · filed 9 February 2026
- ▲ bought on the open market 2,519 shares of VeradermicsSEC Form 49 February 2026Common stock, par value $0.00001 per share · traded 4 February 2026 · filed 9 February 2026
- ▲ bought on the open market 730,370 shares of Benitec BiopharmaSEC Form 410 November 2025Common stock, par value $0.0001 per share · traded 7 November 2025 · filed 10 November 2025
- ▲ bought on the open market 751,111 shares of Benitec BiopharmaSEC Form 410 November 2025Common stock, par value $0.0001 per share · traded 7 November 2025 · filed 10 November 2025
- ▲ bought on the open market 9,503 shares of Benitec BiopharmaSEC Form 42 April 2025Common stock, par value $0.0001 per share · traded 31 March 2025 · filed 2 April 2025
- ▲ bought on the open market 1,267 shares of Benitec BiopharmaSEC Form 42 April 2025Common stock, par value $0.0001 per share · traded 31 March 2025 · filed 2 April 2025
- ▲ bought on the open market 5,057 shares of Benitec BiopharmaSEC Form 42 April 2025Common stock, par value $0.0001 per share · traded 31 March 2025 · filed 2 April 2025
- ▲ bought on the open market 670 shares of Benitec BiopharmaSEC Form 42 April 2025Common stock, par value $0.0001 per share · traded 31 March 2025 · filed 2 April 2025
- ▲ bought on the open market 37,190 shares of Benitec BiopharmaSEC Form 45 December 2024Common stock, par value $0.0001 per share · traded 3 December 2024 · filed 5 December 2024
- ▲ bought on the open market 4,810 shares of Benitec BiopharmaSEC Form 45 December 2024Common stock, par value $0.0001 per share · traded 3 December 2024 · filed 5 December 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.